Kentucky-specific UnitedHealthcare medical policy governing coverage and clinical use of intensity-modulated radiation therapy (IMRT) for individuals 19 years and older; pediatric IMRT (<19) is covered without further review.
Change TypeRevised indications and updated supporting sections
Effective DateJun 1, 2025
Next Review Date
Key ActionSubmit prior authorization with clinical justification showing why non-IMRT techniques cannot meet organ-at-risk constraints or provide comparative dosimetry when requesting IMRT for non-listed indications.
Revised list of conditions for which IMRT for Definitive Therapy for the primary site is proven and medically necessary, adding vulvar cancer and replacing 'anal cancer' with 'anus /anal canal cancer'.
Updated definition of 'Definitive Therapy'.
Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.
State-specificpolicy applies to
Age ≥19applies to individuals
Multipleproven indications
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
IMRT+PBT
not medically necessary
CPT & HCPCScoding provided
1policy revision
Coverage Criteria for IMRT
Proven and Medically Necessary Indications
Covered when treating the primary site for definitive therapy for the following cancer sites:
Primary-site proven indications: IMRT for Definitive Therapy of the primary site for: anus/anal canal cancer; breast cancer when left-sided internal mammary nodes are being treated or for accelerated partial-breast irradiation up to 5 fractions; central nervous system (CNS) tumors including brain, brainstem, and spinal cord (primary or benign); cervical cancer; endometrial cancer; esophageal cancer; head and neck cancers (including lymphoma and solitary plasmacytomas when treatment includes pharynx, larynx [stage III/IV glottic], salivary glands, oral cavity, nasal cavity, paranasal sinuses); mediastinal tumors (e.g., lymphomas, thymomas) including tracheal cancer; non-small cell lung cancer, stage III, undergoing chemoradiation; pancreatic cancer; prostate cancer; vulvar cancer; compensator-based beam modulation when combined with an above IMRT indication; and hippocampal-avoidance whole-brain radiotherapy (HA-WBRT) of up to 10 fractions for brain metastasis.
Case-by-Case Exceptions
Exceptions / case-by-case coverage for conditions not listed above when AT LEAST one of the following is present:
Exception criteria: 1) Use of a clinically appropriate radiation dose and a non-IMRT technique would increase the probability of clinically meaningful normal tissue toxicity, demonstrated by a comparison of IMRT and non-IMRT treatment plans (e.g., 3D-CRT) referencing RTOG or QUANTEC guidance; OR 2) The same or an immediately adjacent area has been previously irradiated and the dose distribution must be sculpted to avoid exceeding the cumulative tolerance dose of nearby normal tissue.
HA-WBRT Criteria
Specific supportive criteria for hippocampal-avoidance WBRT:
HA-WBRT supportive criteria: ECOG performance status ≤ 2 or Karnofsky performance status ≥ 70; prognosis of four months or greater; absence of leptomeningeal disease; up to 10 fractions for brain metastasis.
Guideline-supported Indications
Guideline-aligned coverage rationale
Guideline endorsements: IMRT/VMAT is recommended or preferred by professional guidelines to reduce dose to normal structures and decrease acute/late toxicity for specific tumor sites (e.g., anal carcinoma, APBI for selected breast cases, CNS tumors near critical OARs); when IMRT/VMAT is unavailable, 3D-CRT is an accepted alternative for some CNS indications.
Sources: ACR, ESMO, NCCN, ASTRO
Evidence-supported Benefits
Clinical evidence demonstrating benefit
Evidence of reduced toxicity: Selected clinical studies and trials demonstrate that IMRT (including dose-painted IMRT and APBI-IMRT) reduces acute and/or late grade ≥2–3 GI, hematologic, dermatologic or breast toxicity, and can improve patient-reported outcomes or cosmesis in certain settings without compromising local control (examples include RTOG 0529, Han 2014, Meattini et al. APBI trial, Mills 2024, Padhi 2023).
See cited trials and cohort studies for details
Covered indications per evidence and guidelines
Covered when consistent with professional guidelines and evidence demonstrating toxicity benefit and/or need for OAR sparing
Gynecologic cancers: IMRT is supported for postoperative pelvic radiotherapy (strong recommendation) and conditionally for definitive pelvic RT to reduce acute and chronic GI and GU toxicity; use image guidance (IGRT) for verification.
ASTRO, NCCN, ESGO guidance cited
Endometrial cancer: IMRT is recommended for adjuvant external-beam pelvic RT to reduce acute and late toxicity and is associated with lower patient-reported acute GI/GU toxicity versus conventional RT.
ACR and ASTRO guidance referenced
Esophageal cancer: IMRT or proton therapy may be used when reduction of heart and lung dose is required and is routinely applied in preoperative, definitive, and postoperative settings; evidence shows cardiac/lung dose sparing though survival differences are mixed.
NCCN and comparative studies referenced
Appropriate use of IMRT/PBRT
IMRT (or PBRT) is appropriate when ALL of the following are met:
IMRT appropriate conditions: 1) Tumor site and treatment intent (preoperative, definitive, or postoperative) are among those where IMRT is standard or preferred (e.g., esophageal/esophagogastric junction, oropharynx, nasopharynx, nasal cavity, paranasal sinuses, salivary gland, thyroid); 2) There is a clinical need to reduce dose to specific organs at risk (e.g., heart, lungs, salivary glands, temporal lobes, cochlea, optic structures, larynx, brachial plexus, esophagus, pharyngeal constrictors, hippocampi) that cannot be achieved with 3D techniques; 3) Treatment planning demonstrates that IMRT will achieve OAR sparing while maintaining tumor coverage.
Based on NCCN guidance and comparative planning rationale.
Hippocampal-avoidance WBRT
HA-WBRT is appropriate when ALL of the following are met:
HA-WBRT criteria: 1) Patient is planned for whole-brain radiotherapy for brain metastases; 2) No metastases are present in the hippocampal-avoidance region; 3) Concurrent memantine is administered per trial or customary regimen; 4) Patient has adequate performance status and a prognosis consistent with expected benefit.
Supported by randomized phase III evidence (NRG CC001/Brown et al.) and guideline statements.
HA-WBRT (hippocampal avoidance) coverage criteria
HA‑WBRT plus memantine is supported when ALL of the following are met:
HA-WBRT eligibility: Patient is receiving whole-brain radiotherapy (WBRT); no metastases within the hippocampal-avoidance region (typically within 5 mm of the hippocampus); expected survival of four months or more; good performance status (ECOG ≤2 or KPS ≥70); memantine administered per evidence-based regimen.
Supported by phase III trial (Brown et al.) and ASCO/SNO/ASTRO and NCCN guideline statements indicating cognitive preservation without OS detriment.
Mediastinal/Thymic/ Lymphoma coverage rationale
Use of IMRT/advanced conformal techniques for mediastinal tumors, lymphoma, and thymic tumors is appropriate when ALL of the following apply:
Mediastinal/thymic/lymphoma indications: Advanced RT techniques (IMRT/VMAT/DIBH/IGRT/PBT) are selected to spare critical organs at risk (heart, lungs, esophagus, breast, thyroid) while maintaining target coverage; selection should be based on demonstrable dosimetric advantage and adherence to dose constraints, with special consideration to minimize mean heart dose in younger or long-term survivors.
Supported by systematic reviews and NCCN guidance noting improved conformity and OAR sparing but caution about low-dose bath and need for constraint adherence.
NSCLC Stage III coverage stance
For stage III non-small cell lung cancer (definitive chemoradiation):
NSCLC Stage III IMRT preference: IMRT is preferred over 3D-CRT when it reduces heart dose and/or clinically meaningful lung toxicity; comparative analyses (NRG/RTOG 0617 secondary analyses) showed lower heart V40 and reduced rates of grade ≥3 pneumonitis with IMRT and similar survival and locoregional control, supporting IMRT use especially for unfavorable cardiac location or large PTVs.
NCCN and trial secondary analyses referenced
Pancreatic cancer coverage stance
For pancreatic cancer and locally advanced disease:
Pancreatic IMRT rationale: IMRT/VMAT are appropriate to improve PTV coverage and reduce dose to stomach, duodenum and other OARs; comparative studies and systematic reviews report lower acute and late GI toxicities with IMRT versus 3D-CRT while overall survival and progression-free survival are similar; ASTRO strongly recommends modulated techniques for localized pancreatic cancer.
ASTRO (2019), NCCN, and multiple comparative studies cited
Evidence-supported indications and considerations
Clinical guidance and evidence-supported uses of IMRT cited in this section include the following disease-site recommendations and observations.
Pancreatic cancer: ASTRO strongly recommends modulated techniques such as IMRT/VMAT for localized pancreatic cancer and NCCN recognizes IMRT as increasingly applied to improve PTV coverage and decrease OAR dose.
ASTRO 2019; NCCN 2024
Prostate cancer: Guidelines (ACR, AUA/ASTRO, NCCN) support IMRT as a standard EBRT technique for localized prostate cancer, permit dose escalation, and recommend IMRT for pelvic nodal irradiation with doses between 45 Gy and 52 Gy.
ACR, AUA/ASTRO guidance referenced
Vulvar cancer: ESGO and NCCN recommend IMRT techniques for adjuvant and advanced vulvar cancer (daily set-up verification and image-guided IMRT) to maximize target dose and minimize normal tissue dose.
ESGO 2023; NCCN 2024
Intensity-Modulated Radiation Therapy (IMRT) for Definitive Therapy — Revised indications
Covered when IMRT is indicated as Definitive Therapy for specified primary tumor sites (list revised).
Revised coverage rationale: Policy revision (06/01/2025) updated the list of conditions for which IMRT for Definitive Therapy of the primary site is proven and medically necessary: added vulvar cancer and replaced 'anal cancer' with 'anus/anal canal cancer'.
See full policy body for the complete itemized list of tumor sites and criteria.
Use of IMRT in conjunction with proton beam radiation therapy is considered unproven and not medically necessary due to insufficient evidence of efficacy. Requests combining IMRT and proton therapy in a single treatment plan are unsupported by the identified clinical literature and would be reviewed as not medically necessary per policy guidance.
Some studies reporting benefits of IMRT are limited by small sample sizes and single-center designs; for example, RTOG 0529 (dose-painted IMRT for anal cancer) included 52 evaluable participants and did not meet its primary endpoint despite observing reductions in selected acute toxicities. Authors emphasize these limitations and the importance of radiation quality assurance when interpreting results.
IMRT should not be used as a routine alternative to brachytherapy for treatment of central cervical disease in individuals with an intact cervix. Guideline guidance states brachytherapy remains essential for central disease and deviation to IMRT requires careful justification and reproducible technique to avoid compromising standard of care.
Hippocampal-avoidance whole-brain radiotherapy (HA-WBRT) should not be used when metastases are present in the hippocampal-avoidance region. Eligibility for HA-WBRT requires absence of hippocampal lesions and adherence to trial- and guideline-defined anatomic constraints to achieve the intended cognitive-sparing benefit.
Patients with metastases within the hippocampal-avoidance region are not candidates for HA-WBRT. Professional society guidance recommends offering HA-WBRT plus memantine only to individuals receiving WBRT who have no hippocampal lesions and an expected survival of at least four months.
The clinical literature did not identify evidence supporting the combined use of IMRT and proton beam radiation therapy within a single treatment plan. Such combined-modality plans are unsupported by available studies and therefore lack an evidence base for routine coverage.
This Medical Policy provides interpretive assistance for coverage determinations but does not supersede specific federal, state, or contractual benefit plan terms. When conflicts exist, the applicable federal, state, or contractual requirements govern coverage decisions; providers should verify applicable plan rules before proceeding.
IMRT used in conjunction with proton beam radiation therapy is considered unproven and not medically necessary because there is insufficient clinical evidence demonstrating efficacy or safety for combined IMRT+proton approaches. The literature review identified no supportive trials for this combined modality.
Dose escalation above commonly accepted standards has not consistently improved outcomes and may increase toxicity; for example, escalation to 61.6 Gy to the esophageal primary did not improve local control or survival compared with standard-dose (50.4 Gy) chemoradiation in a randomized trial and was associated with higher serious toxicity.
There is insufficient evidence to support use of IMRT in situations where it does not provide meaningful organ-at-risk (OAR) sparing or improved patient-reported or clinical outcomes compared with conventional techniques. Decisions to use IMRT should be justified by demonstrated dosimetric or clinical benefit over 3D techniques.
Higher-dose radiation regimens, such as 74 Gy with concurrent chemotherapy for unresectable stage III NSCLC, were associated with worse overall survival compared with standard-dose (60 Gy) regimens in randomized data and therefore high-dose approaches outside established standards may be potentially harmful.
No explicit standalone 'Not Medically Necessary' statements beyond those extracted are present in the cited chunks; users should consult the full policy document for the complete list of not medically necessary criteria and any plan-specific exclusions.
Coding and Billing References
Applicable CPT Codes (reference)CPT
77301
Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications.
77338
Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan.
77385
Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple.
77386
Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex.
77387
Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed.
77520
Proton treatment delivery; simple, without compensation.
77522
Proton treatment delivery; simple, with compensation.
77523
Proton treatment delivery; intermediate.
77525
Proton treatment delivery; complex.
Applicable HCPCS/G Codes (reference)HCPCS
G6015
Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session.
G6016
Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session.
G6017
Intra-fraction localization and tracking of target or patient motion during delivery of radiation therapy (e.g., 3D positional tracking, gating, 3D surface tracking), each fraction of treatment.
Clinical dosing examples (no CPT/HCPCS listed)mixed
not explicitly listed
Document provides study dose/fractionation examples rather than explicit billing codes.
Referenced guidelines (no explicit billing codes in this excerpt)mixed
No codes listed
FDA device product codes (informational)mixed
MUJ
FDA product code referenced for IMRT devices
IYE
FDA product code referenced for IMRT devices
Selected dosing examples — Anal DP-IMRT and APBI-IMRT
Anal DP-IMRT example50.4–54 Gy in 28–30 fractions (RTOG 0529 dose-prescription by stage: e.g., 50.4 Gy in 28 fractions or 54 Gy in 30 fractions depending on tumor/node size)
APBI-IMRT example30 Gy in 5 fractions (6 Gy per fraction, delivered over ~2 weeks as in phase III APBI-IMRT trial)
Context noteSelected dosing examples are illustrative clinical prescriptions from cited trials and guideline-aligned studies; individual prescription varies by stage and clinical scenario.
Provider Actions and Prior Authorization Guidance
Prior Authorization
Prior Authorization Expectations and Required Documentation
Prior authorization for IMRT (and when applicable, PBRT) requires clear clinical justification that documents the specific need for a modulated technique for the member in question. Requests must explain why a non-IMRT technique (for example, 3D-CRT) cannot meet organ-at-risk (OAR) dose constraints or would otherwise increase the probability of clinically meaningful normal tissue toxicity. When the indication is guideline-preferred (e.g., prostate pelvic nodal treatment, postoperative pelvic RT, definitive stage III NSCLC with chemoradiation, pancreatic cancer, head and neck, CNS tumors, HA‑WBRT candidacy), reference to the relevant guideline(s) (NCCN, ASTRO, ACR, AUA/ASTRO, ASCO/SNO/ASTRO) should be included in the prior authorization rationale. Comparative dosimetry or planning rationale showing meaningful OAR dose reduction with IMRT versus the proposed non-IMRT alternative should be provided when appropriate. Document the treatment intent (definitive, postoperative/adjuvant, palliative), prior radiation to the same or immediately adjacent area (if applicable), and the clinical circumstances that necessitate sculpting dose to avoid exceeding cumulative normal tissue tolerance.
Include staging and relevant diagnostic information (e.g., TNM, pathology, sites of disease).
Specify prescribed IMRT dose and fractionation and the treatment intent (definitive, adjuvant/postoperative, palliative, salvage).
List concurrent systemic therapy (agent, schedule) when applicable.
Provide prior radiation details if re-irradiation is contemplated (dates, fields, doses).
Definitions and Terminology
Definitive Therapy
DefinitionRadiation treatments for cancer with curative intent.
ContextUsed when treatment intent is to achieve cure rather than palliation; definition updated in 06/01/2025 policy revision.
ReferenceLandsteiner et al., 2023 (policy Definitions section).
IMRT / IGRT
IMRTAn advanced high-precision RT technique using computer-controlled linear accelerators to modulate beam intensity and conform dose to tumor while minimizing dose to surrounding critical structures.
IGRTImaging used throughout planning and delivery to localize targets, verify setup, and adapt therapy for anatomic/positional changes.
Background and Evidence Summary
IMRT is an advanced external beam radiation therapy technique that modulates beam intensity to conform dose to tumor shape and spare nearby normal tissues. It is frequently used with image-guided radiation therapy (IGRT) to maximize precision and may enable targeted dose escalation or reduced dose to critical organs at risk when clinically indicated.
Change TypeRevised indications and updated supporting sections
Effective DateJun 1, 2025
Next Review Date
Key ActionSubmit prior authorization with clinical justification showing why non-IMRT techniques cannot meet organ-at-risk constraints or provide comparative dosimetry when requesting IMRT for non-listed indications.
CNS and head & neck: IMRT and conformal techniques are recommended to achieve target coverage while sparing normal tissues; evidence shows similar oncologic outcomes versus conventional techniques with potential differences in patterns of recurrence and improved OAR sparing.
NCCN and ASTRO guidance and selected studies referenced
Combined IMRT and proton RT: No clinical literature evidence was identified supporting combined use of IMRT and proton beam RT in a single treatment plan.
Implies combined IMRT+PBT plans are unsupported without strong justification
When IMRT is requested for indications not explicitly listed as proven, include either: (1) comparative treatment plans (IMRT vs non-IMRT) demonstrating clinically meaningful OAR sparing per RTOG/QUANTEC constraints, or (2) clinical rationale that non-IMRT would exceed cumulative normal tissue tolerances.
For HA‑WBRT requests, provide brain MRI (or other cross-sectional imaging) demonstrating no metastases within 5 mm of the hippocampi, absence of leptomeningeal disease, ECOG ≤2 or KPS ≥70, and expected survival ≥ 4 months; include memantine plan when applicable.
When IMRT is requested for pancreatic cancer, note that ASTRO strongly recommends modulated techniques (IMRT/VMAT); include site-specific guideline citation and planned dose/fractionation.
If IMRT is proposed alongside proton therapy in the same treatment plan, note this is considered unproven and not medically necessary; such combined-modality plans will be denied.
Quality assurance: include documentation of radiation therapy planning and delivery QA processes (e.g., plan review, motion management/IGRT approach, image guidance schedule). Real-time QA may be required for certain protocols/trials.
FDA device approvals for IMRT systems are informational only and do not by themselves establish coverage (see product codes MUJ and IYE).
Prior authorization determinations are subject to applicable federal, state, or contractual benefit plan requirements which govern if conflicts exist.
Documentation Required
Guideline-Based Justification for Prior Authorization
Guideline-based justification should be cited in the prior authorization when IMRT is requested for disease sites or situations where professional society guidance prefers or strongly recommends IMRT/VMAT (examples include: prostate with pelvic nodal irradiation, CNS grade 2–3 diffuse gliomas, head and neck cancers to spare salivary glands/optic structures, stage III NSCLC undergoing chemoradiation, definitive or postoperative pelvic RT for cervical/uterine cancers, pancreatic cancer, APBI-IMRT for selected early breast cancers, and HA‑WBRT plus memantine for eligible WBRT patients). When guidelines recommend advanced techniques conditionally, include site-specific rationale and plan comparisons if requested.
Reference the exact guideline section and year in the PA submission when possible.
For pancreatic cancer PA requests, indicate adherence to ASTRO recommendations favoring modulated techniques.
For CNS and HA‑WBRT requests, document compliance with imaging and prognostic criteria per ASCO/SNO/ASTRO and NCCN.
Denial Risk
IMRT with Proton Therapy Not Covered
IMRT delivered in conjunction with proton beam radiation therapy in the same treatment plan is considered unproven and not medically necessary. Requests proposing a combined IMRT+proton plan will be denied.
If proton therapy is clinically indicated, submit proton-only plan rationale and supporting evidence separately; do not submit combined IMRT+proton plans.
Refer to the plan applicability note regarding contractual or state-specific coverage differences.
Documentation Required
Quality Assurance Importance
Quality assurance processes are expected to be documented. Real-time radiation QA has been emphasized in prospective IMRT trials and may be required for certain complex or protocol-driven cases.
Provide a description of planning QA, patient-specific QA (e.g., dosimetric verification), and image-guidance strategy (IGRT frequency, motion management).
For trial-based or high-complexity treatments, include evidence of participation in QA programs or central review when available.
Prior Authorization
HA‑WBRT Candidacy and Documentation
Hippocampal-avoidance whole-brain radiation therapy (HA‑WBRT) criteria: HA‑WBRT should be offered only to individuals receiving WBRT who have no metastases within 5 mm of the hippocampus, no leptomeningeal disease, an expected survival of ≥ 4 months, and appropriate performance status (ECOG ≤ 2 or KPS ≥ 70). Memantine should be offered per guideline recommendations when HA‑WBRT is delivered.
Submit brain MRI demonstrating absence of metastases within 5 mm of hippocampi.
Document performance status and estimated prognosis (≥ 4 months).
Include memantine prescription plan when indicated.
Prior Authorization
Documentation for Non-Listed Indications
When IMRT is requested for indications not explicitly listed as proven, submit documentation showing that either (1) a non‑IMRT technique would increase the probability of clinically meaningful normal tissue toxicity (with comparative planning data demonstrating OAR constraint violations), or (2) prior radiation to the same or immediately adjacent area requires sculpting of dose to avoid exceeding cumulative tolerances. Provide site-specific rationale and any relevant guideline citations.
Comparative dosimetry (IMRT vs 3D-CRT) is preferred when available.
If relying on prior radiation history, include prior treatment records (fields, doses, dates).
Documentation Required
Required Treatment Documentation
Required treatment documentation to include with PA requests:
Diagnosis, stage, and pathology.
Prescribed IMRT dose and fractionation and treatment intent.
Concurrent systemic therapy regimen and timing.
Radiation treatment planning summary and OAR constraints with justification.
Imaging used for simulation and target/OAR delineation (CT simulation, MRI, PET when applicable).
Radiation QA plan and IGRT strategy.
Prior radiation records if re-irradiation is planned.
Documentation Required
Justify IMRT Use per Guideline Recommendations
Justify IMRT use per guideline recommendations and clinical context: when guidelines explicitly prefer IMRT to minimize toxicity (e.g., pelvic RT for cervical/uterine cancer, head and neck cancers, prostate with pelvic nodes, stage III NSCLC chemoradiation, pancreatic cancer), cite the guideline and explain how IMRT will achieve the stated goals (e.g., bowel, bone marrow, cardiac or pulmonary sparing).
Include target volumes and nearby critical OARs and describe expected benefit of IMRT for these structures.
If IMRT is preferred per guideline, include the guideline citation and the specific recommendation text when possible.
Documentation Required
Document Clinical Justification and Comparative Dosimetry
Document clinical justification that IMRT (or PBRT when applicable) is required to reduce dose to specific organs at risk. When appropriate, provide comparative dosimetry demonstrating that IMRT meaningfully reduces dose to OARs compared with 3D-CRT or other alternatives.
Specify which OARs require sparing and the anticipated dose reductions with IMRT.
Attach DVH comparisons or planning summaries when available.
Documentation Required
Imaging and Anatomic Documentation
Imaging and anatomic documentation must support technique-specific requests (for example, HA‑WBRT requires MRI to exclude hippocampal involvement). Contouring of targets and OARs should be submitted or summarized to demonstrate that IMRT will achieve the planned sparing without compromising target coverage.
Provide MRI/CT used for simulation and representative contour sets or summary images.
For HA‑WBRT, include hippocampal contours and distance measurements to closest lesions.
Note
FDA Devices (Informational)
The FDA has cleared multiple devices for IMRT delivery (product codes MUJ and IYE). This information is provided for reference only; FDA device clearance does not, by itself, establish coverage or medical necessity.
When using this policy for coverage decisions, check applicable federal, state, or contractual benefit plan requirements as they may supersede or modify the standard policy language. UnitedHealthcare uses InterQual® as the primary medical/surgical criteria; if InterQual lacks applicable criteria, UnitedHealthcare Medical Policies, Coverage Determination Guidelines, and Utilization Review Guidelines approved by the Kentucky Department for Medicaid Services may be used.
In the event of conflict, federal, state, or contractual plan terms govern.
Prior authorization decisions may reference InterQual and other UnitedHealthcare guidelines as noted.
Documentation Required
Consideration of Non-IMRT Alternatives
Consideration of non-IMRT alternatives is expected when IMRT is requested for conditions not explicitly listed as proven. If IMRT is not clearly required, the PA reviewer may request evidence that non‑IMRT techniques were considered and found inadequate.
Describe alternative techniques evaluated (e.g., 3D-CRT, brachytherapy, SBRT) and reasons they are unsuitable for this patient.
If facility lacks IMRT/VMAT capability, note that guidelines may support 3D-CRT as an alternative for some CNS tumors and other sites.
Documentation Required
Alternative Technique Pathway
When IMRT/VMAT is unavailable or not feasible, provide rationale and consider alternative technique pathways (for example, 3D-CRT is an acceptable alternative per ASTRO for certain CNS tumors). This may inform step-therapy or utilization management decisions.
If proposing a non-IMRT alternative, include expected target coverage and OAR constraints achievable with the alternative.
Document equipment or resource limitations when applicable.
Step Therapy
Step Therapy
Step therapy: there are no explicit step therapy sequencing requirements stated in this policy. However, guideline-preferred sequencing (e.g., use of IMRT for pancreatic cancer and other sites where modulated techniques are strongly recommended) should be followed and documented.
For pancreatic cancer, ASTRO strongly recommends modulated techniques (IMRT/VMAT); document adherence to this preference when applicable.
Where step therapy might be considered by a plan, clinical rationale and comparative planning should be provided to avoid inappropriate delays.
Typical useIMRT is often delivered with IGRT to maximize precision and allow higher tumor doses with organ-at-risk sparing.
DP-IMRT (dose-painted IMRT)
Technique descriptionDP-IMRT delivers differential doses (simultaneous integrated boost) to sub-volumes within the target to treat gross disease and elective nodal volumes while sparing normal tissues.
Clinical exampleRTOG 0529 used DP-IMRT in anal cancer with stage-based prescriptions and reported reduced acute hematologic, dermatologic, and GI toxicity.
Planning implicationDP-IMRT enables sculpted dose distribution to deliver higher dose to gross tumor while limiting dose to organs at risk.
APBI-IMRT
Technique descriptionAccelerated partial-breast irradiation delivered using IMRT targeting the surgical bed in selected early-stage breast cancer patients.
Example prescription30 Gy in 5 fractions (6 Gy per fraction) as used in the phase III APBI-IMRT trial (Meattini et al., 2020).
Clinical outcome noteAPBI-IMRT demonstrated similar 10-year ipsilateral breast tumor recurrence and reduced acute/late toxicity versus whole-breast irradiation in select patients.
IMRT preferred indications
Preferred scenariosUse IMRT to minimize acute and chronic toxicity for postoperative pelvic radiotherapy and conditionally for definitive pelvic radiotherapy (e.g., cervical and endometrial cancer).
RationaleIMRT reduces dose to bowel and other critical structures and is recommended with IGRT for safe delivery in pelvic treatments.
LimitationIMRT should not be used as a routine alternative to brachytherapy for central disease in individuals with an intact cervix unless justified.
HA-WBRT
DefinitionWhole-brain radiotherapy planned to spare the hippocampal neural niche using IMRT techniques, typically combined with memantine to reduce cognitive decline.
EvidencePhase III randomized trial (Brown et al., NRG CC001) showed HA-WBRT plus memantine significantly reduced cognitive failure vs WBRT plus memantine without OS detriment.
Eligibility considerationsAppropriate for patients receiving WBRT with no metastases in the hippocampal-avoidance region and adequate prognosis/performance status per guidelines.
DO-IMRT
PurposeAn IMRT planning approach that reduces dose to pharyngeal constrictor muscles and other swallowing-related structures to improve swallowing outcomes.
EvidenceDO-IMRT RCT (Nutting et al., 2023) demonstrated improved swallowing-related patient-reported outcomes versus standard IMRT.
ApplicationUseful in oropharyngeal/hypopharyngeal cancers where dysphagia risk is a major concern and dose to constrictors can be reduced.
HA-WBRT
DefinitionWBRT planned to spare the hippocampal neuroregenerative niche, typically combined with memantine to preserve cognition in eligible patients.
Trial evidencePhase III trial (Brown et al.) and longer-term report (Gondi et al.) document cognitive preservation with HA-WBRT plus memantine versus WBRT plus memantine.
Candidate selectionPatients must have no metastases within the hippocampal-avoidance region and expected survival generally ≥ 4 months per guideline statements.
Advanced RT techniques
Included techniquesAdvanced RT techniques include IMRT, VMAT, deep-inspiration breath hold (DIBH) or respiratory gating, IGRT, 4D-CT planning, and proton beam therapy to achieve highly conformal dose distributions.
PurposeUsed to spare organs at risk while maintaining target coverage in anatomically challenging or high-risk settings.
ConsiderationsTechnique selection should be based on dosimetric advantage and adherence to OAR dose constraints; some approaches may increase low-dose exposure to normal tissues and require careful planning.
Photon energy recommendation for prostate IMRT
RecommendationPhoton energy of at least 6 MV is recommended for prostate IMRT; typical plans use five to nine fields for prostate gland coverage.
RationaleThese technical parameters support achieving highly conformal dose distributions and appropriate target coverage for prostate EBRT.
Guideline sourceACR Appropriateness Criteria and related prostate RT guidance.
IMRT role in prostate cancer
RoleIMRT is a standard external beam radiotherapy technique for clinically localized prostate cancer, supporting dose escalation and pelvic nodal irradiation.
Pelvic nodal dosingGuidelines recommend IMRT for pelvic nodal irradiation with doses between 45 Gy and 52 Gy when indicated.
Guideline backingSupported by AUA/ASTRO and NCCN guidance; IMRT noted as current standard technique for EBRT in prostate cancer.
Definitive Therapy (policy revision)
Revised coverage statementIMRT for Definitive Therapy is covered for a revised list of primary tumor sites; the 06/01/2025 revision added vulvar cancer and replaced 'anal cancer' with 'anus/anal canal cancer'.
ApplicationCoverage applies when IMRT is used with curative intent for listed primary sites per the policy's definitive therapy criteria.
ReferencePolicy History/Revision Information — effective 06/01/2025; see full policy for the complete itemized list of tumor sites.